The medical and surgical treatment of drug-resistant tuberculosis

Journal of Thoracic Disease

Volumn 6, Issue 3, 2014, Pages 186-195

  Calligaro, Gregory L ^a,b   Moodley, Loven ^b   Symons, Greg ^a,b   Dheda, Keertan ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Drug resistance; Extensively drug resistant tuberculosis (XDR TB); Surgery

Indexed keywords

TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DRUG RESISTANT TUBERCULOSIS; HUMAN; INFECTION CONTROL; OUTCOME ASSESSMENT; REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 84896029986     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2013.11.11     Document Type: Review

References (78)

1. Streicher EM, Müller B, Chihota V, et al. Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa. Infect Genet Evol 2012;12:686-94.
2. WHO. Multidrug-resistant tuberculosis (MDR-TB): 2013 Update. Geneva: WHO, 2013.
3. WHO. Multidrug and extensively drug-resistant TB (M/XDR-TB). Geneva: WHO, 2009.
4. Dheda K, Warren RM, Zumla A, et al. Extensively drug-resistant tuberculosis: epidemiology and management challenges. Infect Dis Clin North Am 2010;24:705-25.
5. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010;375:1830-43.
6. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009;9:153-61.
7. Pooran A, Pieterson E, Davids M, et al. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS One 2013;8:e54587.
8. Migliori GB, De Iaco G, Besozzi G, et al. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007;12:E0705171.
9. Udwadia ZF, Pinto LM, Uplekar MW. Tuberculosis management by private practitioners in Mumbai, India: has anything changed in two decades? PLoS One 2010;5:e12023.
10. Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Chest 2009;136:420-5.
11. Van Deun A, Martin A, Palomino JC. Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int J Tuberc Lung Dis 2010;14:131-40.
12. WHO. The use of liquid TB culture and drug susceptibility testing (DST) in low and medium income settings. Geneva, Switzerland: World Health Organization, 2007.
13. World Health Organisation Global Tuberculosis Report 2012 Geneva, Switzerland: World Health Organisation. Available online: http://www. who.int/tb/publications/global_report/en/ (cited 2012 9th November).
14. WHO. Towards universal access to diagnosis and treatment of multidrugresistant and extensively drug-resistant tuberculosis by 2015: WHO progress report 2011. Geneva: WHO, 2011.
15. Dheda K, Theron G, Peter JG, et al. TB drug resistance in high-incidence countries. Tuberculosis. 58: European Respiratory Society Journals Ltd, 2012:95-110.
16. Martin A, Imperiale B, Ravolonandriana P, et al. Prospective multicentre evaluation of the direct nitrate reductase assay for the rapid detection of extensively drug-resistant tuberculosis. J Antimicrob Chemother 2014;69:441-4.
17. Menzies NA, Cohen T, Lin HH, et al. Population health impact and costeffectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med 2012;9:e1001347.
18. Theron G, Peter J, Meldau R, et al. Accuracy and impact of Xpert MTB/ RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid. Thorax 2013;68:1043-51.
19. Steingart KR. Xpert MTB/RIF test for detection of pulmonary tuberculosis and rifampicin resistance. J Evid Based Med 2013;6:58.
20. Peter J, Green C, Hoelscher M, et al. Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments. Curr Opin Pulm Med 2010;16:262-70.
21. Alvarez-Uria G, Azcona JM, Midde M, et al. Rapid Diagnosis of Pulmonary and Extrapulmonary Tuberculosis in HIV-Infected Patients. Comparison of LED Fluorescent Microscopy and the GeneXpert MTB/RIF Assay in a District Hospital in India. Tuberc Res Treat 2012;2012:932862.
22. Chang K, Lu W, Wang J, et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J Infect 2012;64:580-8.
23. WHO. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva: World Health Organization, 2011.
24. Rishi S, Sinha P, Malhotra B, et al. A comparative study for the detection of Mycobacteria by BACTEC MGIT 960, Lowenstein Jensen media and direct AFB smear examination. Indian J Med Microbiol 2007;25:383-6.
25. Smith SE, Kurbatova EV, Cavanaugh JS, et al. Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis. Int J Tuberc Lung Dis 2012;16:203-5.
26. Barnard M, Albert H, Coetzee G, et al. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008;177:787-92.
27. Barnard M, Gey van Pittius NC, van Helden PD, et al. The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay. J Clin Microbiol 2012;50:3712-6.
28. Rutledge JA, Crouch JB. The ultimate results in 1654 cases of tuberculosis treated at the Modern Woodmen of America Sanitorium. Am Rev Tuberc 1919;2:755-63.
29. Hillemann D, Rüsch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009;47:1767-72.
30. Peter JG, Theron G, Muchinga TE, et al. The diagnostic accuracy of urinebased Xpert MTB/RIF in HIV-infected hospitalized patients who are smear-negative or sputum scarce. PLoS One 2012;7:e39966.
31. Patel VB, Theron G, Lenders L, et al. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous meningitis in a high burden setting: a prospective study. PLoS Med 2013;10:e1001536.
32. WHO. Treatment of Tuberculosis: Guidelines. 4th ed. Geneva: WHO, 2009.
33. WHO. Guidelines for the progammatic management of drug-resistant tuberculosis: 2011 update. Geneva: WHO, 2011.
34. Almeida Da Silva PE, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother 2011;66:1417-30.
35. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010;375:1798-807.
36. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009;33:871-81.
37. Cox H, Ford N, Keshavjee S, et al. Rational use of moxifloxacin for tuberculosis treatment. Lancet Infect Dis 2011;11:259-60.
38. Kam KM, Yip CW, Cheung TL, et al. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb Drug Resist 2006;12:7-11.
39. Jacobson KR, Tierney DB, Jeon CY, et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010;51:6-14.
40. Sirgel FA, Donald PR, Odhiambo J, et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 2000;45:859-70.
41. Jayaram R, Shandil RK, Gaonkar S, et al. Isoniazid pharmacokineticspharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2004;48:2951-7.
42. de Steenwinkel JE, de Knegt GJ, ten Kate MT, et al. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J Antimicrob Chemother 2010;65:2582-9.
43. Katiyar SK, Bihari S, Prakash S, et al. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008;12:139-45.
44. Rist N. The ant itubercular act ivity of ethioniamide (alphaethylthioisonicotinamide or Th 1314). An experimental and clinical study. Bibl Tuberc 1960;15:69-126.
45. Gopal M, Padayatchi N, Metcalfe JZ, et al. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013;17:1001-7.
46. Gonzalo X, Drobniewski F. Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate. J Antimicrob Chemother 2013;68:366-9.
47. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397-405.
48. WHO. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. Geneva: WHO, 2013.
49. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367:1508-18.
50. Shean K, Streicher E, Pieterson E, et al. Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa. PLoS One 2013;8:e63057.
51. Harris T, Bardien S, Schaaf HS, et al. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. S Afr Med J 2012;102:363-6.
52. Field SK, Fisher D, Jarand JM, et al. New treatment options for multidrugresistant tuberculosis. Ther Adv Respir Dis 2012;6:255-68.
53. Canetti G. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis 1965;92:687-703.
54. Dravniece G, Cain KP, Holtz TH, et al. Adjunctive resectional lung surgery for extensively drug-resistant tuberculosis. Eur Respir J 2009;34:180-3.
55. Park SK, Kim JH, Kang H, et al. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrugresistant and extensively drug-resistant tuberculosis. Int J Infect Dis 2009;13:170-5.
56. Kempker RR, Rabin AS, Nikolaishvili K, et al. Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis. Clin Infect Dis 2012;54:e51-4.
57. Kaplan G, Post FA, Moreira AL, et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun 2003;71:7099-108.
58. Kempker RR, Vashakidze S, Solomonia N, et al. Surgical treatment of drugresistant tuberculosis. Lancet Infect Dis 2012;12:157-66.
59. Lalloo UG, Naidoo R, Ambaram A. Recent advances in the medical and surgical treatment of multi-drug resistant tuberculosis. Curr Opin Pulm Med 2006;12:179-85.
60. Gimferrer JM, Mestres CA. Role of surgery in drug-resistant pulmonary tuberculosis. Asian Cardiovasc Thorac Ann 2005;13:201-2.
61. Iseman MD, Madsen L, Goble M, et al. Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis. Am Rev Respir Dis 1990;141:623-5.
62. Man MA, Nicolau D. Surgical treatment to increase the success rate of multidrug-resistant tuberculosis. Eur J Cardiothorac Surg 2012;42:e9-12.
63. Kang MW, Kim HK, Choi YS, et al. Surgical treatment for multidrugresistant and extensive drug-resistant tuberculosis. Ann Thorac Surg 2010;89:1597-602.
64. Naidoo R. Active pulmonary tuberculosis: experience with resection in 106 cases. Asian Cardiovasc Thorac Ann 2007;15:134-8.
65. Pomerantz BJ, Cleveland JC Jr, Olson HK, et al. Pulmonary resection for multidrug resistant tuberculosis. J Thorac Cardiovasc Surg 2001;121:448-53.
66. Pomerantz M, Madsen L, Goble M, et al. Surgical management of resistant mycobacterial tuberculosis and other mycobacterial pulmonary infections. Ann Thorac Surg 1991;52:1108-11; discussion 1112.
67. Miller JI Jr. Physiologic evaluation of pulmonary function in the candidate for lung resection. J Thorac Cardiovasc Surg 1993;105:347-51; discussion 351-2.
68. Kosterink JG. Positron emission tomography in the diagnosis and treatment management of tuberculosis. Curr Pharm Des 2011;17:2875-80.
69. Soussan M, Brillet PY, Mekinian A, et al. Patterns of pulmonary tuberculosis on FDG-PET/CT. Eur J Radiol 2012;81:2872-6.
70. Kir A, Inci I, Torun T, et al. Adjuvant resectional surgery improves cure rates in multidrug-resistant tuberculosis. J Thorac Cardiovasc Surg 2006;131:693-6.
71. Gegia M, Kalandadze I, Kempker RR, et al. Adjunctive surgery improves treatment outcomes among patients with multidrug-resistant and extensively drug-resistant tuberculosis. Int J Infect Dis 2012;16:e391-6.
72. Shiraishi Y, Nakajima Y, Katsuragi N, et al. Resectional surgery combined with chemotherapy remains the treatment of choice for multidrug-resistant tuberculosis. J Thorac Cardiovasc Surg 2004;128:523-8.
73. Park SK, Lee CM, Heu JP, et al. A retrospective study for the outcome of pulmonary resection in 49 patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2002;6:143-9.
74. Connery CP, Knoetgen J 3rd, Anagnostopoulos CE, et al. Median sternotomy for pneumonectomy in patients with pulmonary complications of tuberculosis. Ann Thorac Surg 2003;75:1613-7.
75. Yen YT, Wu MH, Lai WW, et al. The role of video-assisted thoracoscopic surgery in therapeutic lung resection for pulmonary tuberculosis. Ann Thorac Surg 2013;95:257-63.
76. Iddriss A, Padayatchi N, Reddy D, et al. Pulmonary resection for extensively drug resistant tuberculosis in Kwazulu-Natal, South Africa. Ann Thorac Surg 2012;94:381-6.
77. Marrone MT, Venkataramanan V, Goodman M, et al. Surgical interventions for drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2013;17:6-16.
78. Dheda K, Migliori GB. The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue? Lancet 2012;379:773-5.